Rapid Identity and Quantity CQA Test for Multivalent mRNA Drug Product Formulations
The COVID-19 pandemic highlighted mRNA as a promising platform for vaccines and therapeutics. Many of the analytical tools used to characterize the critical quality attributes of mRNA are inherently singleplex and are not necessarily optimal from a labor and cost perspective. Here, we demonstrate the feasibility of a multiplexed platform (VaxArray) for efficient identity verification and concentration determination for both monovalent and multivalent mRNA formulations. A model system comprising mRNA constructs for influenza hemagglutinin and neuraminidase was used to characterize the analytical performance metrics for a VaxArray mRNA assay. The assay presented herein had a time to result of less than 2 h, required no PCR-based amplification nor extraction of mRNA from lipid nanoparticles, and exhibited high construct specificity that enabled application to the bivalent mixture. The sensitivity for influenza hemagglutinin and neuraminidase mRNA was sub-µg/mL, which is vaccine-relevant, and the average accuracy (%recovery of a check standard) and precision were 104 ± 2% and 9 ± 2%, respectively.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Vaccines - 10(2022), 10 vom: 12. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gao, Rachel Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CQA |
|---|
| Anmerkungen: |
Date Revised 07.01.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/vaccines10101704 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348129750 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348129750 | ||
| 003 | DE-627 | ||
| 005 | 20231226035447.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/vaccines10101704 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1160.xml |
| 035 | |a (DE-627)NLM348129750 | ||
| 035 | |a (NLM)36298569 | ||
| 035 | |a (PII)1704 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gao, Rachel Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid Identity and Quantity CQA Test for Multivalent mRNA Drug Product Formulations |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.01.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The COVID-19 pandemic highlighted mRNA as a promising platform for vaccines and therapeutics. Many of the analytical tools used to characterize the critical quality attributes of mRNA are inherently singleplex and are not necessarily optimal from a labor and cost perspective. Here, we demonstrate the feasibility of a multiplexed platform (VaxArray) for efficient identity verification and concentration determination for both monovalent and multivalent mRNA formulations. A model system comprising mRNA constructs for influenza hemagglutinin and neuraminidase was used to characterize the analytical performance metrics for a VaxArray mRNA assay. The assay presented herein had a time to result of less than 2 h, required no PCR-based amplification nor extraction of mRNA from lipid nanoparticles, and exhibited high construct specificity that enabled application to the bivalent mixture. The sensitivity for influenza hemagglutinin and neuraminidase mRNA was sub-µg/mL, which is vaccine-relevant, and the average accuracy (%recovery of a check standard) and precision were 104 ± 2% and 9 ± 2%, respectively | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CQA | |
| 650 | 4 | |a VaxArray | |
| 650 | 4 | |a influenza | |
| 650 | 4 | |a lipid nanoparticle | |
| 650 | 4 | |a mRNA vaccine | |
| 650 | 4 | |a multiplexed | |
| 650 | 4 | |a nucleic acid microarray | |
| 700 | 1 | |a Riley, Christine M |e verfasserin |4 aut | |
| 700 | 1 | |a Toth, Evan |e verfasserin |4 aut | |
| 700 | 1 | |a Blair, Rebecca H |e verfasserin |4 aut | |
| 700 | 1 | |a Gerold, Megan N |e verfasserin |4 aut | |
| 700 | 1 | |a McCormick, Caitlin |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Amber W |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Tianjing |e verfasserin |4 aut | |
| 700 | 1 | |a Rowlen, Kathy L |e verfasserin |4 aut | |
| 700 | 1 | |a Dawson, Erica D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccines |d 2012 |g 10(2022), 10 vom: 12. Okt. |w (DE-627)NLM239212347 |x 2076-393X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:10 |g day:12 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/vaccines10101704 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 10 |b 12 |c 10 | ||